Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2022 - 2025)

NewAmsterdam Pharma's Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $769.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 11.03% year-over-year to $769.3 million; the TTM value through Dec 2025 reached $3.2 billion, up 42.44%, while the annual FY2025 figure was $769.3 million, 11.03% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $769.3 million at NewAmsterdam Pharma, down from $786.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $864.6 million in Q4 2024 and bottomed at $347.1 million in Q4 2023.
  • The 4-year median for Liabilities and Shareholders Equity is $655.8 million (2022), against an average of $631.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity crashed 36.0% in 2023 before it surged 149.1% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $542.3 million in 2022, then plummeted by 36.0% to $347.1 million in 2023, then skyrocketed by 149.1% to $864.6 million in 2024, then dropped by 11.03% to $769.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Liabilities and Shareholders Equity are $769.3 million (Q4 2025), $786.4 million (Q3 2025), and $815.1 million (Q2 2025).